Fed’s Powell opens door to potential rate cuts at Jackson Hole
Anthony B. Semedo, a director at Artivion, Inc. (NYSE:AORT), recently acquired a notable amount of the company’s common stock. According to the latest SEC filing, Semedo purchased a total of 2,100 shares on March 5, 2025, in two separate transactions. The shares were bought at prices ranging from $25.25 to $25.327 per share, amounting to a total value of approximately $53,140. According to InvestingPro data, the stock’s RSI suggests oversold conditions, while the company maintains strong liquidity with a current ratio of 4.34x.
The transactions included 1,500 shares acquired directly by Mr. Semedo, intended for his IRA, and an additional 600 shares purchased indirectly through his spouse’s IRA. Post-transaction, Mr. Semedo’s direct ownership in Artivion stands at 35,659 shares, while the shares held indirectly by his spouse amount to 600. The company, with a market capitalization of $1.07 billion, has demonstrated revenue growth of 9.75% in the last twelve months.
These acquisitions reflect Semedo’s continued investment in Artivion, a company specialized in the surgical and medical instruments sector. InvestingPro analysis reveals analyst targets ranging from $30 to $35, with net income expected to grow this year. Get access to 10+ additional ProTips and comprehensive financial analysis with an InvestingPro subscription.
In other recent news, Artivion Inc. reported its fourth-quarter revenue for 2024 at $97.3 million, which fell short of the anticipated $100.82 million. This shortfall was largely due to a cybersecurity breach that impacted sales by approximately $4.5 million. Despite this, Artivion’s adjusted EBITDA for the quarter exceeded expectations, reaching $17.6 million compared to the forecasted $17 million. The company’s full-year revenue for 2024 also did not meet expectations, totaling $388.5 million against the guidance range of $389 million to $396 million. Looking ahead, Artivion projects 2025 revenue to be between $420 million and $435 million, representing a 10-14% growth. Analysts from Stifel, Needham, and JMP Securities have adjusted their price targets for Artivion, with Stifel lowering it to $30, Needham to $32, and JMP maintaining it at $33, all while keeping a Buy or Market Outperform rating. The cybersecurity incident is expected to affect the first quarter of 2025, with projected revenues between $94 million and $98 million, below prior estimates. Despite these challenges, Artivion anticipates a rebound in sales growth throughout 2025, with adjusted EBITDA expected to reach between $83 million and $91 million.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.